NCT06866665View on ClinicalTrials.gov

Antithrombotic Strategy for AF Patients With High Risk CAD

NANot yet recruitingINTERVENTIONAL
Enrollment

1,400

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
Atrial FibrillationCoronary Artery Disease
Interventions
DRUG

Anticoagulation Monotherapy

Participants in the anticoagulation monotherapy group will receive apixaban 5 mg twice daily during the study period.

DRUG

Combination therapy

Participants in the combination therapy group will receive clopiogrel 75 mg daily and apixaban 5 mg twice daily during the study period.

All Listed Sponsors
lead

Yonsei University

OTHER

NCT06866665 - Antithrombotic Strategy for AF Patients With High Risk CAD | Biotech Hunter | Biotech Hunter